Learn more about Peter Attia’s digital program
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
#07 – Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know
“Elevated Lp(a) may have conferred a survival advantage for most of human history: a better ability to deal with acute trauma, but possibly at the expense of poor handling of chronic damage. In today’s environment, for many people, that’s not an advantage.” —Peter Attia
#111 – AMA #14: What lab tests can (and cannot) inform us about our overall objective of longevity
“Metabolic health really matters. It is the common thread that links all of these chronic diseases.” — Peter Attia
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
#185 – Allan Sniderman, M.D.: Cardiovascular disease and why we should change the way we assess risk
“If we’re still saying the same things we said 30 years ago, it could be a problem because we should have learned how to say it better, more accurately.” —Allan Sniderman
The straight dope on cholesterol – Part I
Welcome to a topic near and dear.
1 in 10 people lack access to clean water
There are a lot of things that I find “unacceptable” on a daily basis, but situations like this help put things in perspective.
Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.